Porto Biomed. J. 2017;
150-152 doi: http://dx.doi.org/doi:10.1016/j.pbj.2017.06.002 (Published 31 August 2017)
The path toward an HIV-1 vaccine
Therapeutic Discovery, Amgen, Inc., CA, United States
E-mail address: email@example.com (F. Garces)
Accepted 15 June 2017
HIV is responsible for millions of deaths around the world and in the absence of available treatment capable of a cure, only the vaccine can offer protection against this virus. However, and after three decades of research, such a vaccine remains elusive. Here, I attempt to explain the major challenges on the development of an anti-HIV immunogen, and how the three-dimensional pictures of antibodies interacting with this virus can guide us to the design of a successful vaccine.
Porto Biomedical Journal - issue n.º 5